AMGN
Price
$287.01
Change
-$2.56 (-0.88%)
Updated
Jun 4 closing price
Capitalization
151.69B
61 days until earnings call
GSK
Price
$40.80
Change
+$0.34 (+0.84%)
Updated
Jun 4 closing price
Capitalization
88.13B
55 days until earnings call
Interact to see
Advertisement

AMGN vs GSK

Header iconAMGN vs GSK Comparison
Open Charts AMGN vs GSKBanner chart's image
Amgen
Price$287.01
Change-$2.56 (-0.88%)
Volume$2.34M
Capitalization151.69B
GSK
Price$40.80
Change+$0.34 (+0.84%)
Volume$2.94M
Capitalization88.13B
AMGN vs GSK Comparison Chart
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. GSK commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and GSK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (AMGN: $287.01 vs. GSK: $40.80)
Brand notoriety: AMGN: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 77% vs. GSK: 52%
Market capitalization -- AMGN: $151.69B vs. GSK: $88.13B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • AMGN’s FA Score: 3 green, 2 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than AMGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 6 bullish TA indicator(s).

  • AMGN’s TA Score: 4 bullish, 5 bearish.
  • GSK’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, GSK is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +2.71% price change this week, while GSK (@Pharmaceuticals: Major) price change was +4.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.27%. For the same industry, the average monthly price growth was +2.61%, and the average quarterly price growth was +3.54%.

Reported Earning Dates

AMGN is expected to report earnings on Aug 05, 2025.

GSK is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.27% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($152B) has a higher market cap than GSK($88.1B). AMGN has higher P/E ratio than GSK: AMGN (22.66) vs GSK (14.01). GSK YTD gains are higher at: 23.370 vs. AMGN (12.567). AMGN has higher annual earnings (EBITDA): 14.8B vs. GSK (9.08B). AMGN has more cash in the bank: 10.9B vs. GSK (4.99B). GSK has less debt than AMGN: GSK (18B) vs AMGN (64.6B). GSK has higher revenues than AMGN: GSK (30.3B) vs AMGN (28.2B).
AMGNGSKAMGN / GSK
Capitalization152B88.1B173%
EBITDA14.8B9.08B163%
Gain YTD12.56723.37054%
P/E Ratio22.6614.01162%
Revenue28.2B30.3B93%
Total Cash10.9B4.99B218%
Total Debt64.6B18B359%
FUNDAMENTALS RATINGS
AMGN vs GSK: Fundamental Ratings
AMGN
GSK
OUTLOOK RATING
1..100
812
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
10
Undervalued
PROFIT vs RISK RATING
1..100
3461
SMR RATING
1..100
1341
PRICE GROWTH RATING
1..100
5447
P/E GROWTH RATING
1..100
9119
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (10) in the Pharmaceuticals Major industry is in the same range as AMGN (21) in the Biotechnology industry. This means that GSK’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (34) in the Biotechnology industry is in the same range as GSK (61) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.

AMGN's SMR Rating (13) in the Biotechnology industry is in the same range as GSK (41) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.

GSK's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as AMGN (54) in the Biotechnology industry. This means that GSK’s stock grew similarly to AMGN’s over the last 12 months.

GSK's P/E Growth Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (91) in the Biotechnology industry. This means that GSK’s stock grew significantly faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNGSK
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
49%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
47%
Momentum
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
61%
MACD
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
51%
Advances
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 3 days ago
57%
Declines
ODDS (%)
Bearish Trend 15 days ago
52%
Bearish Trend 22 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
51%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLDR112.732.53
+2.30%
Builders FirstSource
DTSS2.22-0.04
-1.77%
Datasea
GT11.05-0.26
-2.30%
Goodyear Tire & Rubber Company (The)
GPMT2.58-0.10
-3.73%
Granite Point Mortgage Trust
EDN30.51-1.92
-5.92%
Empresa Distribuidora Y Comercializadora Norte SA

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
-0.88%
PFE - AMGN
58%
Loosely correlated
+0.17%
NVS - AMGN
51%
Loosely correlated
+0.86%
GSK - AMGN
50%
Loosely correlated
+0.84%
ABBV - AMGN
49%
Loosely correlated
+0.05%
GILD - AMGN
46%
Loosely correlated
-0.28%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+0.84%
NVS - GSK
61%
Loosely correlated
+0.86%
AZN - GSK
54%
Loosely correlated
+1.64%
PFE - GSK
53%
Loosely correlated
+0.17%
AMGN - GSK
50%
Loosely correlated
-0.88%
SNY - GSK
47%
Loosely correlated
+0.63%
More